POLE and POLD1 encode the catalytic subunits of DNA polymerase epsilon and delta, the two enzymes responsible for replicating the vast majority of the human genome during cell division. Both enzymes carry exonuclease domains that act as molecular proofreaders, excising incorrectly inserted nucleotides before they can become permanent mutations. When the genes encoding these proofreading domains are themselves mutated, the editing function fails. Tumor cells then accumulate errors at an extraordinary pace, a phenomenon sometimes described as an ultramutated or hypermutated phenotype. The resulting flood of abnormal proteins is processed and displayed on the cell surface by human leukocyte antigen molecules, making the tumor look profoundly foreign to the immune system and rendering it unusually vulnerable to immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies.

In the new study, a team led by Yiping Lang and corresponding author Tingting Zhu enrolled 450 consecutive colorectal cancer patients and systematically characterized the mutational profiles of POLE and POLD1, examining how the mutations related to clinicopathological features, immunotherapy efficacy, and survival. The overall mutation frequency was 5.78 percent, meaning roughly one in seventeen patients carried an alteration in at least one of the two genes. Notably, the mutations were heterogeneous in type, and the researchers found no significant association between mutation status and core clinical characteristics, TNM stage, or other tumor features. In other words, a clinician could not guess from a patient’s age, stage, or tumor appearance whether the proofreading machinery was broken; only sequencing could reveal it.

The immunotherapy results were striking. Among patients with POLE or POLD1 mutations, the objective response rate, the proportion whose tumors shrank measurably, reached 72.2 percent, compared with just 27.5 percent in wild-type patients. Disease control, which also includes patients whose tumors stopped growing, was achieved in 94.4 percent of the mutated group versus 71.0 percent of the wild-type group. Survival differences were even more dramatic: median progression-free survival was 16.0 months in patients with mutations versus 9.8 months in those without, and median overall survival was 77.5 months versus 22.7 months. For a disease in which metastatic colorectal cancer has historically been among the least immunotherapy-responsive tumor types, those numbers represent a potential reclassification of an entire molecular subset of patients.

The study also probed the biological mechanisms underlying this heightened sensitivity. Tumors with POLE or POLD1 mutations showed elevated tumor mutation burden, the total count of mutations carried by the cancer cells, which supplies the raw material for neoantigens that the immune system can recognize. They also displayed increased PD-L1 expression, the ligand through which tumors suppress attacking T cells and the direct target of checkpoint inhibitors, as well as enhanced infiltration of the tumor by lymphocytes, the immune cells that must be present and functional for checkpoint blockade to work. Together, these three features paint a coherent picture: proofreading-deficient tumors generate more targets, attract more immune cells, and depend more heavily on the PD-1/PD-L1 axis to escape destruction, making them exquisitely susceptible once that escape route is blocked pharmacologically.

Immune-related adverse events, the inflammatory side effects that arise when a reinvigorated immune system attacks healthy tissue, were also more common in the mutation carriers. However, the severe forms of these toxicities were actually less frequent in the mutated group than in wild-type patients. This asymmetry, more immune activation overall but less severe toxicity, is clinically meaningful, because fears of grade three or higher immune-related adverse events are one factor that can make clinicians hesitant to prescribe checkpoint inhibitors, particularly in older or frailer patients. The data suggest that in this population, the enhanced efficacy of immunotherapy in mutation carriers does not come at the price of a higher burden of dangerous side effects.

Beyond documenting the association, the researchers built and validated an integrated prognostic nomogram, a statistical tool that combines multiple variables into a single score to estimate an individual patient’s risk. The nomogram incorporated POLE and POLD1 mutation status alongside clinical factors and achieved a concordance index of 0.717 for predicting overall survival. A C-index of 0.5 indicates predictions no better than chance, while 1.0 indicates perfect discrimination, so 0.717 represents moderate predictive accuracy, useful for auxiliary risk stratification but not definitive on its own. The authors were careful to note that the tool has restricted clinically applicable threshold ranges, meaning its outputs should be interpreted within defined boundaries rather than treated as a universal oracle.

The significance of the work lies partly in how it complements existing biomarkers. Immunotherapy is currently standard in colorectal cancer primarily for tumors that are microsatellite instability-high or mismatch repair deficient, a subset accounting for only a small fraction of cases, most of them metastatic. POLE and POLD1 proofreading mutations represent a partially overlapping but distinct route to hypermutation. By demonstrating in a large consecutive cohort that these mutations independently predict favorable immunotherapy response and prognosis, the study strengthens the case for including POLE and POLD1 in routine molecular profiling panels for colorectal cancer, potentially extending the benefits of immunotherapy to patients whose tumors would not qualify under MSI testing alone.

There are important caveats. The study was retrospective, with informed consent waived by the ethics committee of Sir Run Run Shaw Hospital for that reason, and it was conducted at Chinese institutions, so the mutation spectrum and treatment patterns may not generalize perfectly to other populations. The mutation frequency of 5.78 percent confirms that POLE and POLD1 alterations are relatively uncommon, which means large multicenter collaborations will be needed to refine the findings and to determine whether specific mutation types, for example exonuclease domain mutations versus variants of uncertain significance, carry different prognostic weight. The moderate C-index of the nomogram likewise signals that mutation status alone cannot capture the full complexity of immunotherapy outcomes, which are shaped by tumor microenvironment factors, prior treatments, and host immunity.

Even so, the study lands at a moment when the field is actively searching for biomarkers that can extend immunotherapy beyond the microsatellite instability-high minority of colorectal cancers. The convergence of high tumor mutation burden, elevated PD-L1 expression, dense lymphocyte infiltration, and exceptional clinical responses in proofreading-deficient tumors offers a mechanistically grounded rationale for prospective trials that stratify patients by POLE and POLD1 status. If those trials confirm what this cohort suggests, a routine sequencing test already performed on most colorectal tumors could quietly become one of the most consequential decisions in the treatment pathway, directing a subset of patients toward therapies their tumors are primed to answer.

Subject of Research: POLE/POLD1 mutations as predictive biomarkers for immunotherapy response and prognosis in colorectal cancer

Article Title: Clinical features and prognostic impact of POLE/POLD1 mutations in colorectal cancer treated with immunotherapy

Article References: Clinical features and prognostic impact of POLE/POLD1 mutations in colorectal cancer treated with immunotherapy. (n.d.). https://doi.org/10.1007/s00432-026-06605-7

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06605-7

Keywords: colorectal cancer, POLE, POLD1, immunotherapy, tumor mutation burden, PD-L1, biomarker, prognosis, immune checkpoint inhibitors, hypermutation, nomogram, tumor-infiltrating lymphocytes